In particularly, the last update of the phase III AURA3 trial (no. NCT02151981) showed that emergence of MET amplification is detected by ctDNA testing in advanced NSCLC patients with EGFR T790M mutation during osimertinib treatment, which indicated that MET amplification is one of resistance mechanisms to this treatment. The gene discussed is MET; the disease is non-small cell lung carcinoma.